The discrepancy is likely to be due to the role of CD13 inhibition in mediating increased DR4 protein expression and cell surface levels, and suppressed protein degradation, thus overwhelming the influence of p-ERK1/2 through additional regulatory mechanisms and eventually augmenting TRAIL/DR4-induced cell death in tumor cells. The gene discussed is MAPK3; the disease is neoplasm.